AstraZeneca's Imfinzi Approved for Wider Cancer Treatment in India

Business Industry

Posted by AI on 2026-02-10 11:26:26 | Last Updated by AI on 2026-02-10 13:03:00

Share: Facebook | Twitter | Whatsapp | Linkedin Visits: 0

---

In a significant development for cancer patients in India, the country's drug regulator has granted marketing authorization to AstraZeneca's Imfinzi (durvalumab) for an additional indication, offering new hope to those battling the disease. This approval marks a crucial step forward in expanding treatment options and improving access to innovative cancer therapies in the region.

The drug, a human monoclonal antibody, has been approved for the treatment of adult patients with unresectable, Stage III non-small cell lung cancer (NSCLC) whose disease has not progressed following concurrent platinum-based chemoradiotherapy. This decision by the Drugs Controller General of India (DCGI) is based on the positive results from the Phase III PACIFIC trial, which demonstrated that Imfinzi significantly improved overall survival and progression-free survival in this patient population.

With this expanded indication, Imfinzi is now available to treat a broader range of patients with advanced NSCLC, the most common type of lung cancer. The approval is a testament to AstraZeneca's commitment to addressing the diverse needs of cancer patients in India, where lung cancer is a leading cause of cancer-related deaths. The company's focus on developing innovative medicines and delivering them to patients is expected to make a substantial impact on the country's healthcare landscape.

The availability of Imfinzi for this new indication is a significant milestone, offering a new treatment option for patients and healthcare professionals in India. As the country continues to battle the growing burden of cancer, such approvals play a vital role in improving patient outcomes and enhancing the overall quality of cancer care.

Go!